Key clinical point: Lack of access to the best chemotherapy drugs in the Brazilian health system suggested as reason for low survival.
Major finding: The median overall survival of all 44 patients submitted to chemotherapy was 12.9 months, with 2- and 3-years estimated overall survival of 24.2% and 9.7%, respectively.
Study details: A retrospective study of 64 patients diagnosed with non-indolent MCL between Jan. 1, 2003 and May 31, 2015.
Disclosures: The authors reported that they had no conflicts of interest.
Brasil SAB et al. Hematol Transfus Cell Ther. 2020; 42(1):93–7.